Recommendations for improving the design, conduct, and analysis of clinical trials in Hospital-acquired pneumonia and ventilator-associated pneumonia

Clinical Infectious Diseases

Volumn 51, Issue SUPPL. 1, 2010, Pages

  Powers, John H ^a  

^a GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NOVOBIOCIN; TETRACYCLINE; ANTIINFECTIVE AGENT;

BACTERIAL PNEUMONIA; CLINICAL TRIAL; CONFERENCE PAPER; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HOSPITAL ACQUIRED PNEUMONIA; HUMAN; MEDICAL DECISION MAKING; PATIENT SELECTION; PRIORITY JOURNAL; PUBLIC HEALTH; UNITED STATES; VENTILATOR ASSOCIATED PNEUMONIA; CLINICAL TRIAL (TOPIC); CROSS INFECTION; HOSPITAL; METHODOLOGY; MICROBIOLOGY; PNEUMONIA, BACTERIAL; PNEUMONIA, VENTILATOR-ASSOCIATED; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; CLINICAL TRIALS AS TOPIC; CROSS INFECTION; HOSPITALS; HUMANS; PNEUMONIA, BACTERIAL; PNEUMONIA, VENTILATOR-ASSOCIATED; RESEARCH DESIGN; TREATMENT OUTCOME; UNITED STATES;

EID: 77955684738     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/653036     Document Type: Conference Paper

References (68)

1. Hopkins WA. Patulin. Biological properties: extended trial in the common cold. Lancet 1943; i:631-634.
2. Medical Research Council. Clinical trial in the common cold. Lancet 1944; i:373-375.
3. World Health Organization. Food-borne hazards. http://www.who.int/ foodsafety/publications/capacity/en/2.pdf. 2009. Accessed 15 May 2010.
4. Anastasi A, Urbina S. Validity: basic concepts. In: Anastasi A, Urbina S, eds. Psychological testing. Upper Saddle River, NJ: Prentice Hall, 1997:113-139.
5. International Conference on Harmonisation. Statistical Principles for Clinical Trials (ICH E-9). http://www.ich.org/LOB/media/MEDIA485.pdf. 1998. Accessed 15 May 2010.
6. International Conference on Harmonisation. Choice of Control Group and Related Issues in Clinical Trials (ICH E-10). http://www.ich.org/LOB/media/ MEDIA486.pdf. 2000. Accessed 15 May 2010.
7. Fleming TR. Current issues in non-inferiority trials. Stat Med 2008; 27(3):317-332.
8. Pocock SJ. The pros and cons of noninferiority trials. Fundam Clin Pharmacol 2003; 17(4):483-490.
9. US Food and Drug Administration. Transcripts of the Anti-Infective Drugs Advisory Committee: doripenem for hospital-acquired pneumonia. http://www.fda.gov/ohrms/dockets/ac/08/minutes/2008-4364m1-Final.pdf. 2008. Accessed 15 May 2010.
10. Basilea Pharmaceuticals. Ceftobiprole press release. http://hugin.info/ 134390/R/1158619/224195.pdf. 2009. Accessed 15 May 2010.
11. Wyeth Pharmaceuticals. Tigecycline. http://www.wyeth.com/news/archive? navpdisplay&navTop/wyeth-html/home/news/pressreleases/2007-1184074360162. html. 2007. Accessed 15 May 2010.
12. Alvarez-Lerma F, Insausti-Ordenana J, Jorda-Marcos R, et al. Efficacy and tolerability of piperacillin/tazobactam versus ceftazidime in association with amikacin for treating nosocomial pneumonia in intensive care patients: a prospective randomized multicenter trial. Intensive Care Med 2001; 27(3):493-502.
13. Brun-Buisson C, Sollet JP, Schweich H, Briere S, Petit C. Treatment of ventilator-associated pneumonia with piperacillin-tazobactam/am-ikacin versus ceftazidime/amikacin: a multicenter, randomized controlled trial. VAP Study Group. Clin Infect Dis 1998; 26(2):346-354.
14. Chastre J, Wunderink R, Prokocimer P, Lee M, Kaniga K, Friedland I. Efficacy and safety of intravenous infusion of doripenem versus imi-penem in ventilator-associated pneumonia: a multicenter, randomized study. Crit Care Med 2008; 36(4):1089-1096.
15. Cometta A, Baumgartner JD, Lew D, et al. Prospective randomized comparison of imipenem monotherapy with imipenem plus netilmicin for treatment of severe infections in nonneutropenic patients. Anti-microb Agents Chemother 1994; 38(6):1309-1313.
16. Fagon J, Patrick H, Haas DW, et al. Treatment of gram-positive nos-ocomial pneumonia. Prospective randomized comparison of quinu-pristin/ dalfopristin versus vancomycin. Nosocomial Pneumonia Group. Am J Respir Crit Care Med 2000; 161(3 Pt 1):753-762.
17. Fink MP, Snydman DR, Niederman MS, et al. Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with im-ipenem-cilastatin. The Severe Pneumonia Study Group. Antimicrob Agents Chemother 1994; 38(3):547-557.
18. Rea-Neto A, Niederman M, Lobo SM, et al. Efficacy and safety of doripenem versus piperacillin/tazobactam in nosocomial pneumonia: a randomized, open-label, multicenter study. Curr Med Res Opin 2008; 24(7):2113-2126.
19. Rubinstein E, Cammarata S, Oliphant T, Wunderink R. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin Infect Dis 2001; 32(3):402-412.
20. West M, Boulanger BR, Fogarty C, et al. Levofloxacin compared with imipenem/cilastatin followed by ciprofloxacin in adult patients with nosocomial pneumonia: a multicenter, prospective, randomized, open-label study. Clin Ther 2003; 25(2):485-506.
21. Wunderink RG, Cammarata SK, Oliphant TH, Kollef MH. Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia. Clin Ther 2003; 25(3):980-992.
22. US Government Printing Office. Federal Food Drug and Cosmetic Act, Section 505(d). http://www.fda.gov/opacom/laws/fdcact/fdcact5a.htm. 2007. Accessed 15 May 2010.
23. US Government Printing Office. US Code of Federal Regulations, Title 21, Part 314.126. http://a257.g.akamaitech.net/7/257/2422/10apr2006-1500/edocket. access.gpo.gov/cfr-2006/aprqtr/21cfr314.126.htm. Accessed 15 May 2010.
24. US Government Printing Office. Federal Food Drug and Cosmetic Act, Section 505(b)(5)(C)(ii). http://www.fda.gov/opacom/laws/fdcact/fdcact5a.htm. Accessed 15 May 2010.
25. Upjohn v Finch, 422 F 2d 944. 1970.
26. Dimasi JA. Risks in new drug development: approval success rates for investigational drugs. Clin Pharmacol Ther 2001; 69(5):297-307.
27. United States v Rutherford, 442 US 544, 78, 605. 1979.
28. Tricoci P, Allen JM, Kramer JM, Califf RM, Smith SC Jr. Scientific evidence underlying the ACC/AHA clinical practice guidelines. JAMA 2009; 301(8):831-841.
29. Lee DH, Vielenmeyer O, Solari P, Chowdhury M. IDSA guidelines: what evidence are they based on? In: Program and abstracts of the 47th Meeting of the Infectious Diseases Society of America (Philadelphia). Arlington, VA: Infectious Diseases Society of American, 2009: 50. Abstract 1324.
30. th Meeting of the Infectious Diseases Society of America (Philadelphia). Arlington, VA: Infectious Diseases Society of American, 2009:79.
31. Miller FG, Rosenstein DL. The therapeutic orientation to clinical trials. N Engl J Med 2003; 348(14):1383-1386.
32. US Department of Health and Human Services. The Belmont Report: ethical principles and guideline for the protection of human subjects of research. http://ohsr.od.nih.gov/guidelines/belmont.html. Accessed 15 May 2010.
33. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002; 288(3):321-333.
34. Chen GF, Johnson MH. Patients' attitudes to the use of placebos: results from a New Zealand survey. N Z Med J 2009; 122(1296):35-46.
35. Ioannidis JP. Why most published research findings are false: author's reply to Goodman and Greenland. PLoS Med 2007; 4(6):e215.
36. Freedman B. Scientific value and validity as ethical requirements for research: a proposed explication. IRB 1987; 9(6):7-10.
37. Powers JH. Noninferiority and equivalence trials: deciphering 'simi-larity' of medical interventions. Stat Med 2008; 27(3):343-352.
38. Fleming TR, Powers JH. Issues in noninferiority trials: the evidence in community-acquired pneumonia. Clin Infect Dis 2008; 47(Suppl 3): S108-S120.
39. Luna CM, Aruj P, Niederman MS, et al. Appropriateness and delay to initiate therapy in ventilator-associated pneumonia. Eur Respir J 2006; 27(1):158-164.
40. Klompas M. Does this patient have ventilator-associated pneumonia? JAMA 2007; 297(14):1583-1593.
41. Fine MJ, Auble TE, Yealy DM et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997; 336(4):243-250.
42. Lim WS, van der Eerden MM, Laing R, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003; 58(5):377-382.
43. Marks HM. The progress of experiment. 1 ed. Cambridge: Cambridge University Press, 2000.
44. Gillings D, Koch G. The application of the principle of intention-to-treat to the analysis of clinical trials. Drug Information J 1991; 25: 411-424.
45. Pertel PE, Bernardo P, Fogarty C, et al. Effects of prior effective therapy on the efficacy of daptomycin and ceftriaxone for the treatment of community-acquired pneumonia. Clin Infect Dis 2008; 46(8): 1142-1151.
46. Powers JH. Reassessing the design, conduct, and analysis of clinical trials of therapy for community-acquired pneumonia. Clin Infect Dis 2008; 46(8):1152-1156.
47. Miettinen OS, Cook EF. Confounding: essence and detection. Am J Epidemiol 1981; 114(4):593-603.
48. LaForce FM. Systemic antimicrobial therapy of nosocomial pneumonia: monotherapy versus combination therapy. Eur J Clin Microbiol Infect Dis 1989; 8(1):61-68.
49. Temple RJ. A regulatory authority's opinion about surrogate endpoints. In: Nimmo WS, Tucker GT, eds. Clinical Measurement in Drug Evaluation. New York: John Wiley and Sons, 1995:3-22.
50. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001; 69(3):89-95.
51. US Government Printing Office. US Code of Federal Regulations, Title 21, Part 314.500 Subpart H. http://a257.g.akamaitech.net/7/257/2422/10apr20061500/ edocket.access.gpo.gov/cfr-2006/aprqtr/21cfr314.126.htm. Accessed 15 May 2010.
52. Federal Register. New drug, antibiotic, and biological drug regulations; accelerated approval. Docket No. 91N-0278. 1992; 57(73):13234-13242.
53. Osler W. Principles and Practice of Medicine. 1 ed. Baltimore: Johns Hopkins University Press, 1892.
54. Kirch W, Schafii C. Misdiagnosis at a university hospital in 4 medical eras. Medicine (Baltimore) 1996; 75(1):29-40.
55. Sharma S, Nadrous HF, Peters SG et al. Pulmonary complications in adult blood and marrow transplant recipients: autopsy findings. Chest 2005; 128(3):1385-1392.
56. Ochoa-Gondar O, Vila-Corcoles A, de DC, et al. The burden of community-acquired pneumonia in the elderly: the Spanish EVAN-65 study. BMC Public Health 2008; 8:222.
57. Lubsen J, Kirwan BA. Combined endpoints: can we use them? Stat Med 2002; 21(19):2959-2970.
58. Patrick DL, Burke LB, Powers JH, et al. Patient-reported outcomes to support medical product labeling claims: FDA perspective. Value Health 2007; 10(Suppl 2):S125-S137.
59. Sheng D, Kim MY. The effects of non-compliance on intent-to-treat analysis of equivalence trials. Stat Med 2006; 25(7):1183-1199.
60. Altman DG, Bland JM. Missing data. BMJ 2007; 334(7590):424.
61. Altman DG. Missing outcomes in randomized trials. Open Med 2009;3: e51-e53.
62. Collen MF, Anderson E. Perspective Kaiser Permanente Medicine 50 years ago. Permanente J 1998; 2(1):22-28.p25.
63. Moye LA, Deswal A. Trials within trials: confirmatory subgroup analyses in controlled clinical experiments. Control Clin Trials 2001; 22(6): 605-619.
64. Pocock SJ. Clinical trials with multiple outcomes: a statistical perspective on their design, analysis, and interpretation. Control Clin Trials 1997; 18(6):530-545.
65. Powers JH, Lin D, Ross D. FDA evaluation of antimicrobials: subgroup analysis. Chest 2005; 127(6):2298-2299.
66. Wunderink RG, Rello J, Cammarata SK, Croos-Dabrera RV, Kollef MH. Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 2003; 124(5):1789-1797.
67. Powers JH. Interpreting the results of clinical trials on antimicrobial agents. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and practice of infectious diseases. Philadelphia: Elsevier Churchill Livingstone, 2005:619-628.
68. Powers JH, Fleming TR. Design, conduct, and analysis of clinical trials in disease due to methicillin-resistant Staphylococcus aureus. Clin Pharmacol Ther 2009; 86(3):244-247.